Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Non-Current Liabilities (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $342.1 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 29.26% to $342.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $342.1 million through Dec 2025, up 29.26% year-over-year, with the annual reading at $342.1 million for FY2025, 29.26% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $342.1 million at Akebia Therapeutics, up from $317.6 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $453.5 million in Q4 2021, with the low at $246.0 million in Q1 2024.
  • Average Total Non-Current Liabilities over 5 years is $322.7 million, with a median of $309.9 million recorded in 2025.
  • The sharpest move saw Total Non-Current Liabilities plummeted 35.04% in 2023, then increased 29.26% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $453.5 million in 2021, then fell by 22.81% to $350.1 million in 2022, then fell by 22.22% to $272.3 million in 2023, then fell by 2.79% to $264.7 million in 2024, then grew by 29.26% to $342.1 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $342.1 million, $317.6 million, and $302.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.